Back to Results
First PageMeta Content
Transcription factors / Diabetes / Intracellular receptors / Fibrates / Organochlorides / Non-alcoholic fatty liver disease / Fenofibrate / Metabolic syndrome / Insulin resistance / Biology / Medicine / Chemistry


Document Date: 2013-03-11 11:48:37

Open Document

File Size: 85,37 KB

Share Result on Facebook

City

Orlando / Barcelona / Boston / PPAR / /

Company

ACS / THOMSON REUTERS / Proc Natl Acad Sci U S A / Genfit SA / /

Country

United States / Spain / /

/

Event

FDA Phase / /

IndustryTerm

therapy for obesity / food effect study / Treatment of Cardiometabolic Disorders / placebo / Diabetes Care / /

MedicalCondition

glucose intolerance / reached epidemic proportions / fatty liver disease / especially abdominal obesity / P.Z. The metabolic syndrome / abdominal obesity / liver dysfunction / fatty liver dysfunction / inflammatory markers / hepatic dysfunction / obesity / gastritis / moderate headache / diarrhea / mild gastroenteritis / Metabolic disorders / cardiovascular diseases / back pain / H. Fatty liver / hepatic fibrosis / multiple abnormalities / glucose disorders / insulin resistance / Cardiovascular disorders / hypertension / atherosclerotic cardiovascular disease / disease / atherosclerosis / chronic liver disease / non-alcoholic fatty liver disease / dyslipidemia / prediabetes / atherogenic dyslipidemia / diabetes / cardiovascular disease / inflammatory component / metabolic syndrome / obesity-associated metabolic disorders / diabetes mellitus / atrial fibrillation / inflammation / S.M. Atherogenic dyslipidemia / Cardiometabolic Disorders / fibrosis / /

MedicalTreatment

hemodilution / /

Organization

Diabetes Assoc / GFT-505 administration / /

Person

Van Gaal / Genfit / /

Position

DISCLOSURES The author / /

Product

triad / simvastatin / glucagon / fenofibrate / GFT505-209 / GFT505209-4 / GFT-505 / GFT505-210 / /

Technology

PHARMACOKINETICS / artificial intelligence / gene expression / condensation / CVD / /

SocialTag